Review of Third-Party Specialty Pharmacy Use for Clinician-Administered Drugs

This legislatively-mandated report examines the prevalence and impact of health insurance payer policies that seek to reduce overall pharmaceutical spending by requiring alternative methods of distribution and payment for certain costly specialty drugs. The clinician-administered drugs subject to these policies, administered not by a retail pharmacy but by a clinician to a patient through injection or infusion in the outpatient setting, are typically high priced and represent a growing share of all pharmaceutical spending.